The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Kadcyla (trastuzumab emtansine), a breast cancer drug currently available through the UK’s Cancer Drugs Fund (CDF).
NICE, the cost-effectiveness watchdog for England and Wales, has reasoned that the drug does not work well enough to justify its high cost, even with the patient access scheme offered by Swiss pharma major Roche (ROG: SIX).
"We are surprised that NICE considered lapatinib in combination with capecitabine as the most relevant comparaThe or"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze